肥厚型心肌病
Hypertrophic Cardiomyopathy.
作者信息
Butt Asra K, Alkhatib Deya, Pour-Ghaz Issa, Isa Sakiru, Al-Taweel Omar, Ugonabo Ifeoma, Yedlapati Neeraja, Jefferies John Lynn
机构信息
Division of Cardiovascular Disease, University of Tennessee Health Science Center, Memphis, TN 38103, USA.
Division of Cardiology, University of Nevada, Las Vegas School of Medicine, Las Vegas, NV 89154, USA.
出版信息
J Cardiovasc Dev Dis. 2023 Mar 2;10(3):106. doi: 10.3390/jcdd10030106.
Abstract
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy resulting from a mutation in one of several cardiac sarcomeric proteins [...].
摘要
肥厚型心肌病（HCM）是最常见的遗传性心肌病，由几种心肌肌节蛋白之一发生突变引起[...]。
相似文献
1
Hypertrophic Cardiomyopathy.肥厚型心肌病
J Cardiovasc Dev Dis. 2023 Mar 2;10(3):106. doi: 10.3390/jcdd10030106.
2
Molecular analysis of sarcomeric and non-sarcomeric genes in patients with hypertrophic cardiomyopathy.肥厚型心肌病患者肌节和非肌节基因的分子分析。
Gene. 2016 Feb 15;577(2):227-35. doi: 10.1016/j.gene.2015.11.048. Epub 2015 Dec 2.
3
Influence of centre expertise on the diagnosis and management of hypertrophic cardiomyopathy: A study from the French register of hypertrophic cardiomyopathy (REMY).中心专业知识对肥厚型心肌病的诊断和治疗的影响：来自法国肥厚型心肌病登记处（REMY）的研究。
Int J Cardiol. 2019 Jan 15;275:107-113. doi: 10.1016/j.ijcard.2018.09.083. Epub 2018 Sep 28.
4
Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals.肥厚型心肌病中与肌节突变相关的临床结局：对 7675 个人的荟萃分析。
Clin Res Cardiol. 2018 Jan;107(1):30-41. doi: 10.1007/s00392-017-1155-5. Epub 2017 Aug 24.
5
Distinct hypertrophic cardiomyopathy genotypes result in convergent sarcomeric proteoform profiles revealed by top-down proteomics.不同肥厚型心肌病基因型导致的相似肌节蛋白构象表型可通过自上而下的蛋白质组学技术揭示。
Proc Natl Acad Sci U S A. 2020 Oct 6;117(40):24691-24700. doi: 10.1073/pnas.2006764117. Epub 2020 Sep 23.
6
Incident Atrial Fibrillation Is Associated With MYH7 Sarcomeric Gene Variation in Hypertrophic Cardiomyopathy.肥厚型心肌病中心律失常与 MYH7 肌球蛋白重链基因突变相关。
Circ Heart Fail. 2018 Sep;11(9):e005191. doi: 10.1161/CIRCHEARTFAILURE.118.005191.
7
Defining the genetic architecture of hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes.定义肥厚型心肌病的遗传结构：重新评估非肌节基因的作用。
Eur Heart J. 2017 Dec 7;38(46):3461-3468. doi: 10.1093/eurheartj/ehw603.
8
The genetic basis of hypertrophic cardiomyopathy in cats and humans.猫和人类肥厚型心肌病的遗传基础。
J Vet Cardiol. 2015 Dec;17 Suppl 1(Suppl 1):S53-73. doi: 10.1016/j.jvc.2015.03.001.
9
Analysis of 8 sarcomeric candidate genes for feline hypertrophic cardiomyopathy mutations in cats with hypertrophic cardiomyopathy.对患有肥厚性心肌病的猫的8个肌节候选基因进行猫肥厚性心肌病突变分析。
J Vet Intern Med. 2009 Jul-Aug;23(4):840-3. doi: 10.1111/j.1939-1676.2009.0341.x.
10
Myocardial Deformation Analysis in and Related Sarcomeric Hypertrophic Cardiomyopathy-The Graz Hypertrophic Cardiomyopathy Registry.心肌变形分析与相关肌节肥厚型心肌病——格拉茨肥厚型心肌病注册研究。
Genes (Basel). 2021 Sep 23;12(10):1469. doi: 10.3390/genes12101469.
引用本文的文献
1
Clinical History of Patients with Hypertrophic Cardiomyopathy-How to Improve the Initiation Process of the Diagnosis?肥厚型心肌病患者的临床病史——如何改善诊断的启动过程？
J Clin Med. 2024 Sep 4;13(17):5239. doi: 10.3390/jcm13175239.
2
Hypertrophic Cardiomyopathy: Genetic Foundations, Outcomes, Interconnections, and Their Modifiers.肥厚型心肌病：遗传基础、结局、相互关系及其修饰因素。
Medicina (Kaunas). 2023 Aug 4;59(8):1424. doi: 10.3390/medicina59081424.
本文引用的文献
1
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy.阿菲卡明治疗梗阻性肥厚型心肌病患者的2期研究。
J Am Coll Cardiol. 2023 Jan 3;81(1):34-45. doi: 10.1016/j.jacc.2022.10.020.
2
Characteristics of Primary Bradyarrhythmia in Hypertrophic Cardiomyopathy: A 10-Year, Single-Center Analysis.肥厚型心肌病原发性心律失常的特征：一项为期10年的单中心分析
J Cardiovasc Dev Dis. 2022 Oct 29;9(11):370. doi: 10.3390/jcdd9110370.
3
Contemporary Diagnosis and Management of Hypertrophic Cardiomyopathy: The Role of Echocardiography and Multimodality Imaging.肥厚型心肌病的当代诊断与管理：超声心动图及多模态成像的作用
J Cardiovasc Dev Dis. 2022 May 25;9(6):169. doi: 10.3390/jcdd9060169.
4
Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review.肥厚型心肌病的诊断与评估：美国心脏病学会心血管造影与介入学会最新临床综述
J Am Coll Cardiol. 2022 Feb 1;79(4):372-389. doi: 10.1016/j.jacc.2021.12.002.
5
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2020 年美国心脏病学会/美国心脏协会肥厚型心肌病诊断和治疗指南：执行摘要：美国心脏病学会/美国心脏协会临床实践指南联合委员会的报告。
Circulation. 2020 Dec 22;142(25):e533-e557. doi: 10.1161/CIR.0000000000000938. Epub 2020 Nov 20.
6
Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM Cardiac Magnetic Resonance Substudy Analysis.马伐卡坦对梗阻性肥厚型心肌病的心脏结构有积极影响：EXPLORER-HCM心脏磁共振亚研究分析。
Circulation. 2021 Feb 9;143(6):606-608. doi: 10.1161/CIRCULATIONAHA.120.052359. Epub 2020 Nov 15.
7
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.马卡丹特治疗有症状梗阻性肥厚型心肌病（EXPLORER-HCM）的随机、双盲、安慰剂对照、3 期临床试验
Lancet. 2020 Sep 12;396(10253):759-769. doi: 10.1016/S0140-6736(20)31792-X. Epub 2020 Aug 29.
8
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy.马卡丹特治疗非梗阻性肥厚型心肌病有症状患者的疗效评估。
J Am Coll Cardiol. 2020 Jun 2;75(21):2649-2660. doi: 10.1016/j.jacc.2020.03.064.
9
Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial.Mavacamten 治疗梗阻性肥厚型心肌病的临床试验。
Ann Intern Med. 2019 Jun 4;170(11):741-748. doi: 10.7326/M18-3016. Epub 2019 Apr 30.
10
Historical Perspectives in the Evolution of Hypertrophic Cardiomyopathy.
Cardiol Clin. 2019 Feb;37(1):1-10. doi: 10.1016/j.ccl.2018.08.001.
Zotero 插件